HDAC-42

Known as: AR-42, HDAC Inhibitor AR-42, OSU-HDAC42 
An orally available phenylbutyrate-derived histone deacetylase (HDAC) inhibitor, with potential antineoplastic activity. Upon oral administration, AR… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2007-2017
0520072017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Multiple myeloma (MM) is a hematological malignancy of plasma cells in the bone marrow. Despite multiple treatment options, MM is… (More)
Is this relevant?
2013
2013
Histone deacetylase (HDAC) inhibitors either alone or in combination with hypomethylating agents have limited clinical effect in… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2011
2011
Multiple myeloma (MM) remains incurable with current therapy, indicating the need for continued development of novel therapeutic… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2011
2011
Human T-lymphotropic virus type 1 (HTLV-1) causes a variety of forms of adult T-cell leukemia/lymphoma (ATL), a refractory CD4… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third leading cause of cancer death worldwide. Drug… (More)
Is this relevant?
2010
2010
Histone hypoacetylation occurs in many cancers and inhibition of histone deacetylation is a promising approach to modulate these… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 4
  • figure 3
Is this relevant?
2010
2010
BACKGROUND While deacetylase (DAC) inhibitors show promise for the treatment of B-cell malignancies, those introduced to date are… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2010
2010
The cytomegalovirus (CMV) promoter is considered to be one of the strongest promoters for driving the in vivo expression of genes… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 4
Is this relevant?
2007
2007
UNLABELLED Hepatocellular carcinoma (HCC) is a leading cause of cancer death worldwide, yet effective therapeutic options for… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
This study reports a histone deacetylation-independent mechanism whereby histone deacetylase (HDAC) inhibitors sensitize prostate… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?